Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance
Tin Phan, Ruy Miguel Ribeiro, Gregory E. Edelstein, Julie Boucau, Rockib Uddin, Caitlin Marino, May Y. Liew, Mamadou Barry, Manish Chandra Choudhary, Dessie Tien, Karry Su, Zahra Reynolds, Yijia Li, Shruti Sagar, Tammy D. Vyas, , Alan S. Perelson
The paper models viral rebound after nirmatrelvir-ritonavir treatment, finding that target cell preservation and incomplete viral clearance drive rebound, with extended treatment reducing this risk.
Journal of Virology · Feb 4, 2025Peer-reviewedImmunology